FDA Compounding Guidances Might Cull Outsourcing List
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency outlines which compounders should consider becoming outsourcers, but process may push some facilities to de-register.
You may also be interested in...
Drug Compounding Can't Be Justified By Price, FDA Says
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.